Health officials are reminding the public that antibiotics are ineffective against respiratory infections caused by viruses, ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

As the 2024-2025 respiratory virus season gets under way, statewide infectious disease experts urge everyone in Oregon to ...

Oregon health officials want to make sure everyone is safe and protected this respiratory virus season with vaccinations and ...

(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...

We are stronger when we are all protected against respiratory diseases,” said Dr. Tomas Aragon, public health officer for ...

RSV is a common respiratory virus that can cause lung infections which can be more serious for newborn babies and older adults, the States of Guernsey said. The vaccine will be su ...

Most people notice this when air pressure changes rapidly, such as when a plane ascends or descends. This happens because the pressurization of the cabin isn't perfect, and the ear pressure is higher ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...